IDEAYA Biosciences Announces Presentations At 2026 European Society of Medical Oncology Meeting October 23-27, Providing Updates Across IDEAYA's Clinical Pipeline
IDEAYA Presentations:2092P (Poster Presentation); Neoadjuvant Darovasertib in Primary Uveal Melanoma: Follow-Up Data from the Phase 2 OptimUM-09 Study. Presenting Author - Mark Shackleton, MBBS, PhD, FRACP, Department
IDEAYA is showing doctors new information about their cancer medicine at a big medical conference in October. When companies share research results like this, it helps people understand if their treatments are working well.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.